Cargando…

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve

Mitral valve prolapse (MVP) patients develop myocardial fibrosis that is not solely explained by volume overload, but the pathophysiology has not been defined. Mineralocorticoid receptor antagonists (MRAs) improve cardiac function by decreasing cardiac fibrosis in other heart diseases. We examined t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibarrola, Jaime, Garaikoetxea, Mattie, Garcia-Peña, Amaia, Matilla, Lara, Jover, Eva, Bonnard, Benjamin, Cuesta, Maria, Fernández-Celis, Amaya, Jaisser, Frederic, López-Andrés, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432373/ https://www.ncbi.nlm.nih.gov/pubmed/32731636 http://dx.doi.org/10.3390/ijms21155372

Ejemplares similares

Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
por: Garcia-Pena, Amaia, et al.
Publicado: (2021)

Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
por: Jover, Eva, et al.
Publicado: (2021)

Myxomatous degeneration of the mitral valve
por: Neto, Felippe Lazar, et al.
Publicado: (2018)

Sex-dependent expression of neutrophil gelatinase-associated lipocalin in aortic stenosis
por: Jover, Eva, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
por: Palacios-Ramirez, Roberto, et al.
Publicado: (2022)

Sex-Differences in Aortic Stenosis: Mechanistic Insights and Clinical Implications
por: Matilla, Lara, et al.
Publicado: (2022)

Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury
por: Nakamura, Toshifumi, et al.
Publicado: (2022)

Targeting Fatty Acid-Binding Protein 4 Improves Pathologic Features of Aortic Stenosis
por: Garaikoetxea, Mattie, et al.
Publicado: (2022)

Distinct Mitral Valve Proteomic Profiles in Rheumatic Heart Disease and Myxomatous Degeneration
por: Martins, Carlo de Oliveira, et al.
Publicado: (2014)

Contractile properties of the right atrial myofilaments in patients with myxomatous mitral valve degeneration
por: Bening, Constanze, et al.
Publicado: (2014)

The Role of Transforming Growth Factor-β Signaling in Myxomatous Mitral Valve Degeneration
por: Tang, Qiyu, et al.
Publicado: (2022)

Characterization of the sex-specific pattern of angiogenesis and lymphangiogenesis in aortic stenosis
por: Matilla, Lara, et al.
Publicado: (2022)

PROX1 Inhibits PDGF-B Expression to Prevent Myxomatous Degeneration of Heart Valves
por: Ho, Yen-Chun, et al.
Publicado: (2023)

Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration
por: PIRINTR, Prapawadee, et al.
Publicado: (2017)

Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration
por: Tan, Karen, et al.
Publicado: (2019)

Myxomatous Mitral Valve with Prolapse and Flail Scallop
por: Fan, Jerry, et al.
Publicado: (2016)

Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration
por: KIJTAWORNRAT, Anusak, et al.
Publicado: (2017)

Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
por: Valente, Carlotta, et al.
Publicado: (2021)

Intestinal Complication With Myxomatous Mitral Valve Diseases in Chihuahuas
por: Araki, R., et al.
Publicado: (2021)

Infectious agents is a risk factor for myxomatous mitral valve degeneration: A case control study
por: Tiveron, Marcos Gradim, et al.
Publicado: (2017)

Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1
por: Tomsič, Katerina, et al.
Publicado: (2023)

Telotristat ethyl reverses myxomatous changes in mice mitral valves
por: Wang, Xinmei, et al.
Publicado: (2022)

Amlodipine decreases mitral regurgitation volume in dogs over 7 days: A study of 24 dogs with myxomatous mitral valve degeneration
por: Park, Sool Yi, et al.
Publicado: (2022)

Myxomatous Mitral Valve Disease with Mitral Valve Prolapse and Mitral Annular Disjunction: Clinical and Functional Significance of the Coincidence
por: Wunderlich, Nina C., et al.
Publicado: (2021)

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
por: Zhao, Min, et al.
Publicado: (2019)

Mitral valvuloplasty with left atrial appendage closure and pacemaker implantation in a dog with severe myxomatous mitral valve degeneration: a case report
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model
por: Ibarrola, Jaime, et al.
Publicado: (2017)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease
por: Menciotti, Giulio, et al.
Publicado: (2017)

Assessment of heart rate turbulence in dogs with myxomatous mitral valve disease
por: dos Santos, Julio P., et al.
Publicado: (2021)

Pro-Inflammatory and Immunological Profile of Dogs with Myxomatous Mitral Valve Disease
por: Piantedosi, Diego, et al.
Publicado: (2022)

Antioxidant capacity of lipid- and water-soluble antioxidants in dogs with subclinical myxomatous mitral valve degeneration anaesthetised with propofol or sevoflurane
por: Tomsič, Katerina, et al.
Publicado: (2020)

Hemodynamic Effects of Protamine Infusion in Dogs with Myxomatous Mitral Valve Disease Undergoing Mitral Valvuloplasty
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Mapping of the myxomatous mitral valve: The three-dimensional extension of mitral annular disjunction in surgically repaired mitral prolapse
por: Biondi, Raoul, et al.
Publicado: (2022)

Mitral annular disjunction in myxomatous mitral valve disease: a relevant abnormality recognizable by transthoracic echocardiography
por: Carmo, Pedro, et al.
Publicado: (2010)

Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease
por: Li, Qinghong, et al.
Publicado: (2015)

Prevalence and Prognostic Importance of Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Borgarelli, M., et al.
Publicado: (2015)

Predictive model for the detection of pulmonary hypertension in dogs with myxomatous mitral valve disease
por: MIKAWA, Shoma, et al.
Publicado: (2014)

Genomic analysis in patients with myxomatous mitral valve prolapse: current state of knowledge
por: Gasser, S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m9uctr9l59nd2tqn4gutllfep9